Quest Diagnostics had its Relative Strength (RS) Rating upgraded from 67 to 71 Friday — a welcome improvement, but still below the 80 or higher score you look for.
IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best stocks often have an RS Rating north of 80 as they launch their largest price moves. See if Quest Diagnostics can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Quest Diagnostics is not currently near a potential buy zone. See if the stock goes on to form a base that could ignite a new run.
Taking a look at revenue and profit performance, Quest Diagnostics has posted two quarters of increasing earnings growth. Revenue growth has also increased over the same time frame.
Quest Diagnostics holds the No. 11 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Castle Biosciences and Guardian Pharmacy Svcs are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
